Tubulis generates uniquely matched antibody-drug conjugates (ADCs) through the combination of novel proprietary technologies and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of protein-drug conjugates by increasing design flexibility while overcoming constraints of toxicity, efficacy, and indication. Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.
The Tubulis Approach:
A broad technology suite to expand the treatment horizon of ADCs